Side effects have been reported for emtricitabine and/or tenofovir disoproxil fumarate (DF) when taken in combination with other antiretroviral agents.
The most common side effects reported in HIV--infected patients during a clinical study of efavirenz, emtricitabine, and tenofovir DF included diarrhea, nausea, fatigue, headache, dizziness, depression, insomnia, abnormal dreams, and rash.
In this trial, emtricitabine-tenofovir DF (with efavirenz) was used from weeks  to , replacing emtricitabine plus tenofovir DF (with efavirenz).
In HIV--uninfected individuals in preexposure prophylaxis trials, the most common side effects reported with emtricitabine-tenofovir DF were headache, abdominal pain, and decreased weight.
Emtricitabine-tenofovir DF:-Very common ( or more): Increased fasting cholesterol (up to )-Common ( to ): Decreased phosphorus, increased fasting triglycerides, altered serum glucose, weight loss, hyperglycemia, increased alkaline phosphataseEmtricitabine and tenofovir alafenamide:-Frequency not reported: Increased total cholesterol, increased low-density lipoprotein (LDL) cholesterol, increased high-density lipoprotein (HDL) cholesterol, increased triglyceridesEmtricitabine:-Common ( to ): Hyperglycemia, hypertriglyceridemia, increased or decreased serum glucose-Frequency not reported: Lactic acidosisTenofovir DF:-Very common ( or more): Hypophosphatemia, increased triglycerides-Common ( to ): Anorexia, weight loss, increased serum glucose-Uncommon ( to ): Hypokalemia-Rare (less than ): Lactic acidosisAntiretroviral therapy:-Frequency not reported: Redistribution/accumulation of body fat (including central obesity, dorsocervical fat enlargement, peripheral wasting, facial wasting, breast enlargement, "cushingoid appearance"), increased blood lipid levels, increased glucose levels
Increased fasting cholesterol (greater than  mg/dL: up to ), decreased phosphorus ( to less than the lower limit of normal: up to ; less than  mg/dL: up to ), increased fasting triglycerides (greater than  mg/dL: up to ), altered serum glucose (less than  mg/dL or greater than  mg/dL: up to ), hyperglycemia (greater than  mg/dL: up to ), and increased alkaline phosphatase (greater than  units/L: ) have been reported with emtricitabine-tenofovir DF.
In clinical trials, the following mean increases were reported in antiretroviral therapy-naive patients after using emtricitabine plus tenofovir alafenamide with elvitegravir plus cobicistat for  weeks: total cholesterol increased by  mg/dL, LDL cholesterol by  mg/dL, HDL cholesterol by  mg/dL, and triglycerides by  mg/dL.
Lactic acidosis and severe hepatomegaly with steatosis (including fatal cases) have been reported with the use of nucleoside analogs.
Hypokalemia and hypophosphatemia may occur as a result of proximal renal tubulopathy.
Hypokalemia, lactic acidosis, and hypophosphatemia have also been reported during postmarketing experience with tenofovir DF.
Increased AST ( to less than  times the upper limit of normal [ to less than  x ULN]: up to ; greater than  x ULN: up to ), ALT ( to less than  x ULN: up to ; greater than  x ULN: up to ), and bilirubin (greater than  x ULN: up to ) have been reported with emtricitabine-tenofovir DF.
Increased AST (greater than  units/L) and ALT (greater than  units/L) have been reported in  and  of males using emtricitabine-tenofovir DF, respectively.
Increased AST (greater than  units/L) and ALT (greater than  units/L) have been reported in  and  of females using emtricitabine-tenofovir DF, respectively.
Severe acute exacerbations of hepatitis have been reported in patients with hepatitis B after discontinuation of this drug and were associated with liver failure and liver decompensation in some emtricitabine-treated patients.
Lactic acidosis and severe hepatomegaly with steatosis (including fatal cases) have been reported with the use of nucleoside analogs.
Hepatic steatosis and hepatitis have also been reported during postmarketing experience with tenofovir DF.
Emtricitabine-tenofovir DF:-Very common ( or more): Increased AST (up to ), increased ALT (up to )-Common ( to ): Increased bilirubin-Frequency not reported: Severe acute exacerbations of hepatitis BEmtricitabine:-Common ( to ): Increased serum AST and/or increased serum ALT, hyperbilirubinemia-Frequency not reported: Liver failure, liver decompensationTenofovir DF:-Common ( to ): Increased transaminases (AST and/or ALT)-Rare (less than ): Hepatic steatosis, hepatitis-Frequency not reported: Lactic acidosis/severe hepatomegaly with steatosis-Postmarketing reports: Increased liver enzymes (primarily AST, ALT, GGT)
Decreased neutrophils ( to /mm: up to ; less than /mm: up to ) and hemoglobin ( to  mg/dL: ; less than  mg/dL: up to ) have been reported with emtricitabine-tenofovir DF.
Emtricitabine-tenofovir DF:-Very common ( or more): Decreased neutrophils (up to )-Common ( to ): Decreased hemoglobinEmtricitabine:-Common ( to ): Neutropenia-Uncommon ( to ): AnemiaTenofovir DF:-Common ( to ): Decreased neutrophils
Emtricitabine-tenofovir DF:-Very common ( or more): Pharyngitis (up to )-Common ( to ): Sinusitis, upper respiratory tract infections, nasopharyngitisEmtricitabine or tenofovir DF:-Common ( to ): Increased cough, pneumonia, rhinitisEmtricitabine:-Very common ( or more): Rhinitis, increased coughTenofovir DF:-Common ( to ): Pneumonia-Postmarketing reports: Dyspnea
Increased serum amylase (greater than  units/L: up to ), pancreatic amylase (greater than  x ULN: up to ), and serum lipase (greater than  x ULN: up to ) have been reported with emtricitabine-tenofovir DF.
In clinical trials, nausea was the most common side effect reported in antiretroviral therapy-naive HIV--infected patients using emtricitabine plus tenofovir alafenamide with elvitegravir plus cobicistat.
Pancreatitis, abdominal pain, and increased amylase have also been reported during postmarketing experience with tenofovir DF.
Emtricitabine-tenofovir DF:-Common ( to ): Diarrhea, nausea, increased serum amylase, abdominal pain, increased pancreatic amylase, increased serum lipase, vomiting-Frequency not reported: FlatulenceEmtricitabine and tenofovir alafenamide:-Common ( to ): NauseaEmtricitabine or tenofovir DF:-Common ( to ): Dyspepsia, abdominal painEmtricitabine:-Very common ( or more): Diarrhea, nausea, abdominal pain-Common ( to ): Increased amylase (including increased pancreatic amylase), increased serum lipase, vomiting, dyspepsiaTenofovir DF:-Very common ( or more): Diarrhea, vomiting, nausea-Common ( to ): Abdominal pain, abdominal distension, flatulence, dyspepsia, increased serum amylase-Uncommon ( to ): Pancreatitis
Emtricitabine-tenofovir DF:-Common ( to ): Depression, insomnia, abnormal dreams, anxietyEmtricitabine or tenofovir DF:-Common ( to ): AnxietyEmtricitabine:-Very common ( or more): Insomnia, abnormal dreams-Common ( to ): Depressive disordersTenofovir DF:-Very common ( or more): Depression-Common ( to ): Insomnia, anxiety
Emtricitabine-tenofovir DF:-Common ( to ): Dizziness, headache-Frequency not reported: SomnolenceEmtricitabine or tenofovir DF:-Common ( to ): Peripheral neuropathy (including neuropathy, peripheral neuritis), paresthesiaEmtricitabine:-Very common ( or more): Dizziness, headache-Common ( to ): Neuropathy/peripheral neuritis, paresthesiaTenofovir DF:-Very common ( or more): Dizziness, headache-Common ( to ): Peripheral neuropathy (including neuropathy, peripheral neuritis)
Asthenia has also been reported during postmarketing experience with tenofovir DF.
Emtricitabine-tenofovir DF:-Common ( to ): Fatigue, syphilis, secondary syphilisEmtricitabine or tenofovir DF:-Common ( to ): Pain, feverEmtricitabine:-Very common ( or more): Asthenia-Common ( to ): PainTenofovir DF:-Very common ( or more): Pain, asthenia-Common ( to ): Chest pain, fever-Frequency not reported: Higher , vitamin D levelsAntiretroviral therapy:-Frequency not reported: Increased weight
Emtricitabine-tenofovir DF:-Common ( to ): Rash event (including rash, maculopapular rash, exfoliative rash, generalized rash, macular rash, pruritic rash, vesicular rash)Emtricitabine:-Very common ( or more): Rash event (including rash, pruritus, maculopapular rash, urticaria, vesiculobullous rash, pustular rash, allergic reaction)-Common ( to ): Skin discoloration (palmar-plantar hyperpigmentation)-Frequency not reported: Lipodystrophy-Postmarketing reports: AngioedemaTenofovir DF:-Very common ( or more): Rash event (including rash, pruritus, maculopapular rash, urticaria, vesiculobullous rash, pustular rash)-Common ( to ): Sweating-Uncommon ( to ): Lipodystrophy-Rare (less than ): Angioedema
Rash has also been reported during postmarketing experience with tenofovir DF.
Increased creatine kinase (males: greater than  units/L; females: greater than  units/L) has been reported in up to  of patients using emtricitabine-tenofovir DF.
In clinical trials, a significant decline in BMD was seen in  of therapy-naive HIV--infected patients using emtricitabine plus tenofovir alafenamide with elvitegravir plus cobicistat.
In virologically-suppressed tenofovir DF-treated patients who switched to emtricitabine plus tenofovir alafenamide with elvitegravir plus cobicistat, mean BMD increased between baseline and week ; decreased BMD was also reported.
Rhabdomyolysis, osteomalacia, muscular weakness, and myopathy may occur as a result of proximal renal tubulopathy.
Rhabdomyolysis, muscular weakness, and myopathy have also been reported during postmarketing experience with tenofovir DF.
Emtricitabine-tenofovir DF:-Common ( to ): Increased creatine kinase, bone fractures-Frequency not reported: Decreased bone mineral density (BMD)Emtricitabine and tenofovir alafenamide:-Very common ( or more): Decreased BMD-Uncommon ( to ): Fractures (excluding fingers and toes)-Frequency not reported: Increased biochemical markers of bone metabolism, increased BMDEmtricitabine or tenofovir DF:-Common ( to ): Myalgia, arthralgia, back painEmtricitabine:-Very common ( or more): Increased creatine kinase-Common ( to ): Myalgia, arthralgiaTenofovir DF:-Very common ( or more): Increased creatine kinase-Common ( to ): Myalgia, arthralgia, back pain-Uncommon ( to ): Rhabdomyolysis, muscular weakness-Rare (less than ): Myopathy-Frequency not reported: Decreased BMD, increased biochemical markers of bone metabolism-Postmarketing reports: Osteomalacia (manifested as bone pain and which may contribute to fractures)Combination antiretroviral therapy:-Frequency not reported: Osteonecrosis
Increased creatinine ( to  x ULN: up to ; greater than  x ULN: less than ) has been reported with emtricitabine-tenofovir DF.
In  trials in antiretroviral therapy-naive HIV--infected patients (median estimated glomerular filtration rate [eGFR]  mL/min at baseline) using emtricitabine plus tenofovir alafenamide with elvitegravir plus cobicistat, mean serum creatinine increased by  mg/dL from baseline to week ; median UPCR was  mg/g at baseline and at week   In a trial in virologically-suppressed tenofovir DF-treated patients (mean eGFR  mL/min at baseline) who switched to emtricitabine plus tenofovir alafenamide with elvitegravir plus cobicistat, mean serum creatinine was similar to baseline; median UPCR was  mg/g at baseline and  mg/g at week   In a trial in renal dysfunction patients (baseline eGFR  to  mL/min) using emtricitabine plus tenofovir alafenamide with elvitegravir plus cobicistat, mean serum creatinine was  mg/dL at baseline and week ; median UPCR was  mg/g at baseline and  mg/g at week Proximal renal tubulopathy generally resolved or improved after tenofovir DF was stopped; however, decreased CrCl did not completely resolve in some patients after stopping the drug.
Rhabdomyolysis, osteomalacia, bone abnormalities (infrequently contributing to fractures), hypokalemia, muscular weakness, myopathy, and hypophosphatemia may occur as a result of proximal renal tubulopathy.
Renal failure, acute renal failure, Fanconi syndrome, proximal renal tubulopathy, increased creatinine, nephrogenic diabetes insipidus, and acute tubular necrosis have also been reported during postmarketing experience with tenofovir DF.
Emtricitabine-tenofovir DF:-Common ( to ): Increased creatinineEmtricitabine and tenofovir alafenamide:-Frequency not reported: Increased serum creatinine, decreased urine protein-to-creatinine ratio (UPCR), worsening renal functionTenofovir DF:-Uncommon ( to ): Increased creatinine-Rare (less than ): Renal failure (acute and chronic), acute tubular necrosis, proximal renal tubulopathy (including Fanconi syndrome), nephrogenic diabetes insipidus-Frequency not reported: New onset or worsening renal impairment-Postmarketing reports: Renal insufficiency, interstitial nephritis (including acute cases)Tenofovir prodrugs:-Frequency not reported: Renal impairment (including renal failure, Fanconi syndrome)
Emtricitabine-tenofovir DF:-Common ( to ): Proteinuria, urethritis, urinary tract infection, hematuria, genital ulceration, anogenital warts-Uncommon ( to ): Proteinuria, glycosuriaTenofovir DF:-Common ( to ): Glycosuria, hematuria-Uncommon ( to ): Proteinuria-Postmarketing reports: Polyuria
Increased glycosuria (+ or greater: less than ) and hematuria (greater than  red blood cells/high power field: up to ) have been reported with emtricitabine-tenofovir DF.
Proteinuria has also been reported during postmarketing experience with tenofovir DF.
Emtricitabine-tenofovir DF:-Frequency not reported: Immune reconstitution/reactivation syndrome, autoimmune disorders in the setting of immune reconstitution (, Graves' disease, polymyositis, Guillain-Barre syndrome)
Emtricitabine:-Common ( to ): Allergic reactionTenofovir DF:-Postmarketing reports: Allergic reaction (including angioedema)
Tenofovir DF:-Frequency not reported: Higher serum parathyroid hormone levels
Abdominal or stomach discomfort
bloody urine
bone pain
dark urine
decreased appetite
decreased frequency or amount of urine
diarrhea
fast, shallow breathing
general feeling of discomfort
increased thirst
light-colored stools
loss of appetite
lower back or side pain
muscle pain or cramping
nausea and vomiting
shortness of breath
sleepiness
swelling of the face, fingers, or lower legs
troubled breathing
unusual tiredness or weakness
upper right abdominal or stomach pain
weight gain
yellow eyes and skin
Weight gain around your neck, upper back, breast, or waist